The award highlights the company’s foundation in advanced academic research and its mission to bring scientific innovation into real clinical practice

Madrid, Spain – 2EyesVision has been named winner of the Santander X Award | Startup Universitaria 2025, granted by the Fundación General CSIC and Banco Santander. The award recognizes startups born in research institutions that have successfully bridged science and market. For 2EyesVision, it affirms a journey rooted in the Spanish National Research Council (CSIC) and driven by a mission: to turn frontier science into tools that improve real-world patient outcomes.

What is the Santander X Award?

The Santander X Award | Startup Universitaria 2025 is part of a broader initiative to promote scientific entrepreneurship in Spain. It honors early-stage companies born from academic or research institutions that have shown significant progress in translating innovation into sustainable business and societal value. The award includes visibility, mentorship, and participation in the national Santander X Spain Awards | Startup & Scaleup 2025.

Why this matters for 2EyesVision

This recognition celebrates the scientific roots and clinical ambition of 2EyesVision. The company’s flagship product, SimVis Gekko2, enables patients to preview their post-surgery vision by simulating different intraocular lenses in real time. The technology, developed in collaboration with CSIC, is already being used in over 18 countries and validated in more than 25 peer-reviewed publications.

“This recognition reinforces our mission to bring scientific innovation closer to the patient and demonstrates the relevance of research-based entrepreneurship,” said Carlos Dorronsoro, CEO and co-founder of 2EyesVision.

Scaling innovation

With backing from Bullnet Capital, CDTI-Innvierte, and ENISA, 2EyesVision continues to grow its international presence, expanding access to personalized vision care.

Follow us on LinkedIn to stay up to date with our latest achievements and innovations:

Discover SimVis Gekko2 and how it’s transforming ophthalmic care:

Interested in investing in 2EyesVision?

Learn more here: